Overcoming the reticuloendothelial
system (RES) has long been a
vital challenge to nanoparticles as drug carriers. Modification of
nanoparticles with polyethylene glycol helps them avoid clearance
by macrophages but also suppresses their internalization by target
cells. To overcome this paradox, we developed an RES-specific blocking
system utilizing a “don’t-eat-us” strategy. First,
a CD47-derived, enzyme-resistant peptide ligand was designed and placed
on liposomes (d-self-peptide-labeled liposome, DSL). After
mainline administration, DSL was quickly adsorbed onto hepatic phagocyte
membranes (including those of Kupffer cells and liver sinusoidal endothelial
cells), forming a long-lasting mask that enclosed the cell membranes
and thus reducing interactions between phagocytes and subsequently
injected nanoparticles. Compared with blank conventional liposomes
(CL), DSL blocked the RES at a much lower dose, and the effect was
sustained for a much longer time, highly prolonging the elimination
half-life of the subsequently injected nanoparticles. This “don’t-eat-us”
strategy by DSL was further verified on the brain-targeted delivery
against a cryptococcal meningitis model, providing dramatically enhanced
brain accumulation of the targeted delivery system and superior therapeutic
outcome of model drug Amphotericin B compared with CL. Our study demonstrates
a strategy that blocks the RES by masking phagocyte surfaces to prolong
nanoparticle circulation time without excess modification and illustrates
its utility in enhancing nanoparticle delivery.
Cell membrane cloaking is an emerging field in drug delivery in which specific functions of parent cells are conferred to newly formed biomimetic vehicles. A growing variety of delivery systems with diverse surface properties have been utilized for this strategy, but it is unclear whether the affinity of membrane−core pairs could guarantee effective and proper camouflaging. In this study, we propose a concise and effective "molecular affinity" strategy using the intracellular domain of transmembrane receptors as "grippers" during membrane coating. Red blood cell (RBC) membranes and cationic liposomes were adopted for fabrication, and a peptide ligand derived from the cytoplasmic protein P4.2 was prepared to specifically recognize the cytoplasmic domain of band 3, a key transmembrane receptor of erythrocytes. Once anchored onto the liposome surface, the P4.2-derived peptide would interact with the isolated RBC membrane, forming a "hidden peptide button", which ensures the right-side-out orientation. The membrane-coated liposomes exhibited an appropriate size distribution around 100 nm and high stability, with superior circulation durations compared with those of conventional PEGylated liposomes. Importantly, they possessed the ability to target Candida albicans by the interaction between the pathogenic fungus and host erythrocytes and to neutralize hemotoxin secreted by the pathogenic fungi. The curative effect of the model drug was thus substantially improved. In summary, the "molecular affinity" strategy may provide a powerful and universal approach for the construction of cell membrane-coated biomaterials and nanomedicines at both laboratory and industrial scales.
Anisotropic modification on nanodiscs could trigger huge differences in their endocytosis mode and following behaviors. In article number https://doi.org/10.1002/adfm.201700406 Zhifei Dai, Qiang Zhang, and co‐workers design analyze the cellular uptake of nanoparticulates differing in anisotropy of shape and ligand modification. This anisotropy‐based approach is promising for manipulating the biointeraction mode of nanomaterials and its outcome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.